Drugs / CRS3123
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06988423 | Apr → Jun 2025 | — | Crestone, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02106338 | Jun → Dec 2014 | Clostridium infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01551004 | May 2012 → Apr 2014 | Clostridium difficile colitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04781387 | Jan 2021 → Apr 2024 | Clostridium infectious disease | Crestone, Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRS3123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06988423 ↗ |
| Known as | REP-3123 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297370 ↗ |
| Action | Inhibit | “inhibits bacterial methionyl-tRNA synthetase” PMID 28584140 ↗ Jul 2017 |
| Modality | Small molecule | “CRS3123 is a novel small molecule” PMID 31685472 ↗ Dec 2019 |
| Route | Oral | “CRS3123 is an oral agent” PMID 28584140 ↗ Jul 2017 |